CRI Funded Scientists

Zebin Xiao, MD, PhD, Postdoctoral Fellow

University of Pennsylvania

Pancreatic ductal adenocarcinoma is a lethal disease expected to become the second leading cause of cancer death in the United States by 2025. A major barrier to effective treatment of PDA is the extensive remodeling of the surrounding connective tissue that the cancer cells usurp to support their growth. This remodeled tissue forms a physical barrier that limits access of potentially therapeutic treatments to the cancer cells, suppresses the immune systems attempts to inhibit tumor growth, and attenuates efficacy of immunotherapies. Dr.Puré’s lab and others have identified a population of non-malignant connective tissue cells referred to as cancer-associated fibroblasts (CAFs), that expands remarkably and is activated in the context of pancreatic cancer. They have also established that this population plays a major role in promoting the development and progression, as well as therapeutic resistance, in pancreatic cancer. 

Projects and Grants

Impact of FAP+ stromal cell depletion on the immune landscape of pancreatic ductal adenocarcinoma

University of Pennsylvania | All Cancers | 2022 | Ellen Puré, Ph.D.

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.